Group 1 - Fosun Pharma announced that its subsidiary, Fosun Kerry, signed a capital increase agreement with Shenzhen Biomedical Industry Fund for a total investment of 600 million yuan, aimed at supporting the operational and business development of Fosun Kerry [1] - The investment will be made in phases, with the new registered capital not exceeding 524.44 million yuan [1] - A co-investment agreement was also signed with 14 participants, including current directors and core management, who will contribute a total of 3.525 million yuan to the new registered capital of 3.081 million yuan [1] Group 2 - The co-investors include several directors and senior management, which constitutes a related party transaction under the Shanghai Stock Exchange Listing Rules [2] - These related party investors plan to contribute a total of 1.246664 million yuan to the new registered capital of 1.089664 million yuan [2] - An incentive plan was approved to attract and retain key talents, allowing for the issuance of equity rights worth up to 93.22 million yuan, with the first batch not exceeding 76.18 million yuan [2] Group 3 - The first batch of incentive rights includes several directors and senior management, also constituting a related party transaction [3] - If all incentive rights are fully vested, these related party investors could indirectly hold 12.76 million yuan of registered capital through a total investment of 9.694159 million yuan [3]

Core Points - Fosun Pharma announced a capital increase agreement with Shenzhen Biomedical Industry Fund for its subsidiary Fosun Kerry, involving a total investment of 600 million yuan for A-round financing [1] - The funds raised will be used for the operation and business development of Fosun Kerry and/or its subsidiaries [1] - A co-investment agreement was signed with 14 participants, including current directors and core management, committing a total of 3.525 million yuan to increase Fosun Kerry's registered capital [1] - The pre-investment valuation for this co-investment aligns with the capital increase [1] Related Transactions - The co-investors include several directors and senior management, which constitutes a related party transaction under the Shanghai Stock Exchange Listing Rules [2] - These related party co-investors plan to contribute a total of 1.246664 million yuan to increase Fosun Kerry's registered capital [2] Incentive Plan - To attract and retain key talent, Fosun Kerry's board approved an incentive plan on October 17, 2025, allowing for the issuance of equity incentives valued at up to 93.219893 million yuan [3] - The first batch of incentives will grant up to 76.184870 million yuan in registered capital [3] - The equity incentives will be sourced from shares transferred to the incentive platform by Fosun Pharma's subsidiary [3] Related Party Incentives - The first batch of incentive recipients includes several directors and senior management, which also constitutes a related party transaction [4] - If all granted incentives are fully vested, these related party recipients could indirectly hold 12.755472 million yuan in registered capital through an investment of 9.694159 million yuan [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲美國FDA孤兒藥資格認定的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 中國，上海 2025 年1 0 月1 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《上海 復健股權投資基金管理有限公司擬投資涉及的復星凱瑞（上海）生物科技有限公司股東全部 權益價值項目資產評估報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 0 月1 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 上海復星醫藥（集團）股份有限公司 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司增資擴股、實施跟投及採納並實施股權激勵暨關聯交易的公告》，僅供參閱。 承董事會命 董事長 陳玉卿 中國，上海 2025 年1 0 月1 7 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received Orphan-drug Designation from the FDA for its investigational drug HLX43, aimed at treating thymic epithelial tumors (TETs) [1] Group 1: Drug Development - HLX43 is a targeted PD-L1 antibody-drug conjugate (ADC) developed by Fuhong Hanlin, combining a novel DNA topoisomerase I inhibitor small molecule toxin-peptide linker with an independently developed PD-L1 targeting antibody [1] - The drug is intended for the treatment of advanced/metastatic solid tumors [1]

Core Points - Fosun Pharma (600196.SH) announced that the Shenzhen Biopharmaceutical Industry Fund intends to participate in the A-round financing of its subsidiary, Fosun Kairui, with a total investment of 600 million yuan to subscribe for no more than 524.44 million yuan of new registered capital [1] - To motivate the core team of Fosun Kairui, 14 co-investors, including current directors and core management, plan to invest a total of 3.525 million yuan to subscribe for 3.081 million yuan of new registered capital [1] - A stock incentive plan was approved by the board of directors and shareholders' meeting of Fosun Kairui, allowing the issuance of incentive rights corresponding to no more than 93.22 million yuan of registered capital at a price of 0.76 yuan per 1 yuan of registered capital [1] Shareholding Structure - After the completion of the capital increase, co-investment, and stock incentive plan, the group's shareholding in Fosun Kairui will decrease from approximately 97.78% to a maximum of 77.10%, while Fosun Kairui will remain a controlled subsidiary of the company [2]

证券代码：600196 股票简称：复星医药 编号：临 2025-160 上海复星医药（集团）股份有限公司 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"） 在研药品注射用 HLX43（即靶向 PD-L1 抗体偶联药物，以下简称"HLX43"）用于胸 腺上皮肿瘤（TETs）治疗获得美国 FDA（即美国食品药品监督管理局，下同）的孤 儿药资格认定（Orphan-drug Designation）。 二、HLX43 的基本信息及研究情况 HLX43 为复宏汉霖利用许可引进的新型 DNA 拓扑异构酶 I 抑制剂小分子毒素-肽 链连接子与其自主研发的靶向 PD-L1 的抗体进行偶联开发的靶向 PD-L1 的抗体偶联 药物（ADC），拟用于晚期/转移性实体瘤的治疗。截至本公告日期（即 2025 年 10 月 17 日，下同），HLX43 的主要研发进展情况如下： 1 适应症 进展 HLX43 单药 晚期/转移性实体瘤 （包括胸腺癌（TC）） 中国境内 1：处于 I 期临床试验阶段；其中， 胸腺癌（TC）队列为国际多中心试验 美国 ...

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kerry, is set to receive a total investment of 600 million yuan from the Shenzhen Biopharmaceutical Industry Fund as part of its Series A financing round, aimed at enhancing the company's growth and retaining key talent [1] Group 1: Financing and Investment - The Shenzhen Biopharmaceutical Industry Fund plans to invest a total of 600 million yuan in Fosun Kerry, contributing to a maximum of 524.44 million yuan in new registered capital [1] - A total of 14 participants, including current directors and core management of Fosun Kerry, will invest 3.525 million yuan through a co-investment platform, contributing to a total of 3.081 million yuan in new registered capital [1] Group 2: Equity Incentive Plan - To motivate and retain key personnel crucial for Fosun Kerry's business growth, the company will implement an equity incentive plan approved by both the board of directors and the shareholders' meeting [1] - The incentive plan will allow for the issuance of equity rights amounting to no more than 93.22 million yuan in registered capital, with the first batch not exceeding 76.18 million yuan [1] Group 3: Shareholding Structure - Following the completion of the financing, co-investment, and equity incentive plan, the group's shareholding in Fosun Kerry will decrease from approximately 97.78% to a maximum of 77.10%, while still maintaining control over the subsidiary [2]

证券代码：600196 股票简称：复星医药 编号：临 2025-159 上海复星医药（集团）股份有限公司 由于本公司若干董事、高级管理人员兼任深圳生物医药产业基金（系本公司之 联营企业）之投委会成员，根据上证所《上市规则》，深圳生物医药产业基金构成 本公司关联方、本次增资构成本公司的关联交易。 2、本次跟投 为充分调动复星凯瑞核心团队的积极性和创造性,于本次增资同时，包括复星凯 瑞现任董事及核心管理层在内的 14 名跟投参与方拟通过跟投平台共计出资 352.50 万元认缴复星凯瑞合计 308.1070 万元的新增注册资本。本次跟投的投前估值与本次 增资一致。 由于跟投参与方包括本公司董事陈玉卿先生、关晓晖女士及高级管理人员刘毅 先生、Xingli Wang 先生、Wenjie Zhang 先生、冯蓉丽女士、朱悦女士，根据上证 所《上市规则》，该等人士构成本公司关联方、其参与本次跟投构成本公司的关联 交易。 关于控股子公司增资扩股、实施跟投 及采纳并实施股权激励暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重 ...